vs
ABVC BIOPHARMA, INC.（ABVC）与Arcadia Biosciences, Inc.（RKDA）财务数据对比。点击上方公司名可切换其他公司
Arcadia Biosciences, Inc.的季度营收约是ABVC BIOPHARMA, INC.的1.1倍（$901.0K vs $796.0K），Arcadia Biosciences, Inc.净利率更高（-148.3% vs -256.6%，领先108.3%），ABVC BIOPHARMA, INC.同比增速更快（104.5% vs -25.8%），过去两年ABVC BIOPHARMA, INC.的营收复合增速更高（1041.5% vs -4.5%）
ABVC生物制药是一家处于临床阶段的生物制药企业，专注于开发肿瘤、眼科、中枢神经系统疾病等领域的创新治疗方案，业务覆盖北美及亚洲主要市场，多款自研候选药物正处于临床试验推进阶段。
阿卡迪亚生物科学是一家美国上市农业生物技术企业，总部位于加利福尼亚州戴维斯，专注于开发可提升作物品质与产量的作物性状改良技术，该公司部分股权归道德指南针公司所有。
ABVC vs RKDA — 直观对比
营收规模更大
RKDA
是对方的1.1倍
$796.0K
营收增速更快
ABVC
高出130.3%
-25.8%
净利率更高
RKDA
高出108.3%
-256.6%
两年增速更快
ABVC
近两年复合增速
-4.5%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $796.0K | $901.0K |
| 净利润 | $-2.0M | $-1.3M |
| 毛利率 | 100.0% | 21.4% |
| 营业利润率 | -246.8% | -152.8% |
| 净利率 | -256.6% | -148.3% |
| 营收同比 | 104.5% | -25.8% |
| 净利润同比 | -417.4% | 67.1% |
| 每股收益（稀释后） | $-0.09 | $-0.97 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ABVCRKDA
| Q4 25 | — | $901.0K | ||
| Q3 25 | $796.0K | $1.3M | ||
| Q2 25 | — | $1.5M | ||
| Q1 25 | — | $1.2M | ||
| Q4 24 | $2.0K | $1.2M | ||
| Q3 24 | $389.3K | $1.5M | ||
| Q2 24 | $117.1K | $1.3M | ||
| Q1 24 | $1.2K | $987.0K |
净利润ABVCRKDA
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-2.0M | $856.0K | ||
| Q2 25 | — | $-4.5M | ||
| Q1 25 | — | $2.6M | ||
| Q4 24 | — | $-4.1M | ||
| Q3 24 | $-394.8K | $-1.6M | ||
| Q2 24 | $-942.3K | $1.1M | ||
| Q1 24 | $-2.8M | $-2.4M |
毛利率ABVCRKDA
| Q4 25 | — | 21.4% | ||
| Q3 25 | 100.0% | 32.1% | ||
| Q2 25 | — | 43.4% | ||
| Q1 25 | — | 43.2% | ||
| Q4 24 | 100.0% | 31.9% | ||
| Q3 24 | 99.9% | 32.9% | ||
| Q2 24 | 99.8% | 51.5% | ||
| Q1 24 | 77.0% | 52.3% |
营业利润率ABVCRKDA
| Q4 25 | — | -152.8% | ||
| Q3 25 | -246.8% | -88.5% | ||
| Q2 25 | — | -34.4% | ||
| Q1 25 | — | 44.2% | ||
| Q4 24 | — | -187.7% | ||
| Q3 24 | -77.7% | -114.5% | ||
| Q2 24 | -734.2% | — | ||
| Q1 24 | -235539.8% | -160.9% |
净利率ABVCRKDA
| Q4 25 | — | -148.3% | ||
| Q3 25 | -256.6% | 65.7% | ||
| Q2 25 | — | -306.4% | ||
| Q1 25 | — | 216.6% | ||
| Q4 24 | — | -334.5% | ||
| Q3 24 | -101.4% | -104.9% | ||
| Q2 24 | -804.4% | 81.2% | ||
| Q1 24 | -235203.2% | -245.5% |
每股收益（稀释后）ABVCRKDA
| Q4 25 | — | $-0.97 | ||
| Q3 25 | $-0.09 | $0.62 | ||
| Q2 25 | — | $-3.26 | ||
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-2.99 | ||
| Q3 24 | $-0.03 | $-1.18 | ||
| Q2 24 | $-0.08 | $0.78 | ||
| Q1 24 | $-0.29 | $-1.78 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.2K | $4.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $12.1M | $4.1M |
| 总资产 | $21.2M | $6.5M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ABVCRKDA
| Q4 25 | — | $4.6M | ||
| Q3 25 | $257.2K | $5.9M | ||
| Q2 25 | — | $4.4M | ||
| Q1 25 | — | $3.2M | ||
| Q4 24 | $313.1K | $4.2M | ||
| Q3 24 | $208.2K | $6.6M | ||
| Q2 24 | $200.0K | $8.1M | ||
| Q1 24 | $106.4K | $8.5M |
股东权益ABVCRKDA
| Q4 25 | — | $4.1M | ||
| Q3 25 | $12.1M | $5.4M | ||
| Q2 25 | — | $4.5M | ||
| Q1 25 | — | $8.9M | ||
| Q4 24 | $1.2M | $6.2M | ||
| Q3 24 | $1.6M | $10.3M | ||
| Q2 24 | $1.8M | $11.7M | ||
| Q1 24 | $1.7M | $10.6M |
总资产ABVCRKDA
| Q4 25 | — | $6.5M | ||
| Q3 25 | $21.2M | $8.6M | ||
| Q2 25 | — | $7.8M | ||
| Q1 25 | — | $13.0M | ||
| Q4 24 | $7.5M | $13.5M | ||
| Q3 24 | $7.8M | $15.2M | ||
| Q2 24 | $8.0M | $17.4M | ||
| Q1 24 | $8.0M | $16.0M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-964.7K | $-861.0K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | 0.0% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流ABVCRKDA
| Q4 25 | — | $-861.0K | ||
| Q3 25 | $-964.7K | $-257.0K | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-1.6M | ||
| Q4 24 | $-1.8M | $-2.2M | ||
| Q3 24 | $60.2K | $-1.8M | ||
| Q2 24 | $-211.4K | $-2.5M | ||
| Q1 24 | $-955.8K | $-3.2M |
自由现金流ABVCRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | $-2.5M | ||
| Q1 24 | — | $-3.2M |
自由现金流率ABVCRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -188.3% | ||
| Q1 24 | — | -326.5% |
资本支出强度ABVCRKDA
| Q4 25 | — | 0.0% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 0.0% | ||
| Q1 25 | — | 0.0% | ||
| Q4 24 | — | 0.0% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.2% | ||
| Q1 24 | — | 1.3% |
现金转化率ABVCRKDA
| Q4 25 | — | — | ||
| Q3 25 | — | -0.30× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.61× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -2.31× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
